Pharmaceuticals APAC News & Press Release Distribution

Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets

* Gennisium finds a strategic partner with global experience and connections in the pharmaceutical industry to accelerate its development in neonatology. * Pierre Fabre strengthens its activities in the field of rare diseases, and more specifically pediatric ones. * This partnership paves th...

2022-10-10 15:00 2743

The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and o...

2022-10-10 08:23 4301

The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma

ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and o...

2022-10-10 08:20 3861

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19

--The multiple-dose escalation Phase I clinical trial will enroll 72 healthy subjects including 60 subjects in 6 dose escalation cohorts and 12 subjects in food effect trial. The enrollment is expected to be completed in the fourth quarter of 2022 --ASC10 is an oral double prodrug. After oral ...

2022-10-10 08:10 3217

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes

HANGZHOU, China and SAN FRANCISCO, Oct. 10, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of dosing in a Phase 1 clinical trial ev...

2022-10-10 08:00 3463

WuXi Biologics Co., Ltd. Removed from Unverified List

WUXI, China, Oct. 10, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List (UVL) by the U....

2022-10-10 07:55 5228

Everest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections

SHANGHAI, Oct. 8, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest Medicines", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, annou...

2022-10-08 08:00 4078

Synapse Medicine Initiates Multi-Site Implementation Study with Leading U.S Hospitals

* Synapse Medicine clinical decision support technology analyzes drug-related risks based on each patient's clinical characteristics and will be studied for its impact on inpatient pharmacist efficacy and efficiency. * The Synapse Medicine medication reconciliation tool will be deployed throu...

2022-10-07 07:05 2702

TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions

* For people with early Alzheimer's (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals * For people with mild to moderate Alzheimer's, HMTM stabilised cognition and funct...

2022-10-06 18:00 2576

Cytiva strengthens cell line development with CEVEC acquisition

* Viral vector manufacturing and cell line development are keystone technologies in the making of gene therapies * 46 scientific experts based in Cologne, Germany, join the Cytiva team in the genomic medicine space * Cytiva customers will have immediate access to technologies that solve som...

2022-10-06 14:00 2237

Servier unveils its 2030 ambition and reveals a new visual identity

* A new ambition by 2030 to accelerate its transformation dynamic * A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal PARIS, Oct. 6, 2022 /PRNewswire/ -- Servier today unveils its 2030 ambition as well as a new visual identity that reflec...

2022-10-06 13:30 2585

ASTRAZENECA, First Organization in Egypt receiving Best place to work for Millennials Award

CAIRO, Oct. 5, 2022 /PRNewswire/ -- AstraZeneca Egypt, was recently certified as a Best Place to Work for Millennials marking it the first organization in Egypt to receive such award. The certification is based on an HR analysis of the company policies focusing on Millennials and an anonymous emp...

2022-10-05 22:59 1766

Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH

-- ASC41 is ranking first in China and third in the world in terms of clinical progress as a thyroid hormone receptor β (THRβ) agonist drug candidate for non-alcoholic steatohepatitis (NASH). ASC41 Phase II clinical trial is currently the most advanced 52-week Phase II clinical trial which is in...

2022-10-05 08:10 3892

Transcenta Received IND Clearance from FDA for Its Best-In-Class MASP2 Targeting Antibody TST004 for the Treatment of IgA Nephropathy

SUZHOU, China, Oct. 5, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that TST004, its best...

2022-10-05 08:00 3238

HAVAS HEALTH & YOU APPOINTS PAUL PFLEIDERER AS PRESIDENT OF HAVAS LIFE NEW YORK

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- As the rapid evolution of the health and wellness sector continues to necessitate innovative thinking and activation across the industry, Havas Health & You today announced that it has appointed seasoned strategic leaderPaul Pfleiderer as President of Havas ...

2022-10-04 21:00 1593

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research LAUSANNE, Switzerland, Oct. 3, 2022 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global bioph...

2022-10-03 15:00 2394

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2023

GOTHENBURG, Sweden, Oct.1, 2022 /PRNewswire/ -- Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee for the company's Annual General Meeting 2023 has been appointed. ...

2022-10-01 00:53 3141

YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.

* Transaction values YS Biopharma at pre-money equity value of $834 million * Certain investors ("Forward Purchase Investors") are expected to invest $30 million in a private placement concurrently with the closing of the business combination transaction pursuant to certain forward purchase ag...

2022-09-30 04:01 3246

First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent

MELBOURNE, Australia, Sept. 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose inNew Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known ...

2022-09-30 02:30 3436

Doxy.me extends telemedicine's reach to 88% of the world's population

Doxy.me adds over 100 languages, live interpreters, and global currencies to overcome barriers to telemedicine around the world. CHARLESTON, S.C., Sept. 30, 2022 /PRNewswire/ -- Doxy.me, the web-based telemedicine platform on a mission to make telemedicine available to all, is expanding its capa...

2022-09-29 22:03 2542